Biohaven (BHVN) Expected to Announce Earnings on Monday

Biohaven (NYSE:BHVN) is expected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Biohaven to post earnings of ($0.86) per share and revenue of $0.2670 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 12:30 PM ET.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, March 2nd. The company reported ($1.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.01. On average, analysts expect Biohaven to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Biohaven Stock Performance

Shares of NYSE BHVN traded up $0.43 during trading on Monday, hitting $10.06. The company had a trading volume of 675,640 shares, compared to its average volume of 2,396,794. The stock has a 50 day simple moving average of $9.91 and a 200 day simple moving average of $11.07. The company has a debt-to-equity ratio of 4.59, a quick ratio of 3.18 and a current ratio of 3.18. Biohaven has a 12 month low of $7.48 and a 12 month high of $23.37. The firm has a market capitalization of $1.51 billion, a P/E ratio of -1.47 and a beta of 1.32.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BHVN. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a research note on Monday, March 9th. Citigroup lifted their target price on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Canaccord Genuity Group began coverage on Biohaven in a report on Monday, April 13th. They issued a “buy” rating and a $21.00 target price for the company. The Goldman Sachs Group upgraded Biohaven to a “strong-buy” rating in a report on Friday, February 6th. Finally, Royal Bank Of Canada upped their target price on Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.53.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BHVN. Suvretta Capital Management LLC raised its position in shares of Biohaven by 83.0% in the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock worth $116,140,000 after acquiring an additional 4,666,666 shares in the last quarter. Infinitum Asset Management LLC raised its position in shares of Biohaven by 267.6% in the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after acquiring an additional 4,550,000 shares in the last quarter. Stifel Financial Corp raised its position in shares of Biohaven by 50.3% in the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after acquiring an additional 3,328,506 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its position in shares of Biohaven by 3,829.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,606,777 shares of the company’s stock worth $18,141,000 after acquiring an additional 1,565,891 shares in the last quarter. Finally, State Street Corp raised its position in shares of Biohaven by 34.2% in the 4th quarter. State Street Corp now owns 5,716,487 shares of the company’s stock worth $64,539,000 after acquiring an additional 1,458,204 shares in the last quarter. 88.78% of the stock is owned by institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.